SCHEMBL4490749

SCHEMBL4490749

Cc1cc(C(C)C(N)C(=O)O)cc(Cl)c1O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C2 P52895 3/20 0.38
AKR1C3 P42330 1/20 0.38
ALOX15 P16050 2/20 0.36
HSD17B10 Q99714 2/20 0.36
CYP1A2 P05177 2/20 0.36
CYP2C9 P11712 2/20 0.36
CYP2C19 P33261 2/20 0.36
ALOX12 P18054 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HIF1A Q16665 1/20 0.36
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
PKM P14618 1/20 0.35
HTT P42858 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35
SLC7A5 Q01650 1/20 0.34
TTR P02766 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15105338 0.83 APP (0.39) AKR1C2AKR1C3ALOX15HSD17B10CYP1A2
SCHEMBL15105368 0.81 ACHE (0.47) AKR1C2AKR1C3HSD17B10ALDH1A1GAA
SCHEMBL4492055 0.77 GAA (0.35) AKR1C2AKR1C3ALOX15HSD17B10CYP1A2
SCHEMBL15105440 0.76 TDP1 (0.49) HSD17B10CYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL16883538 0.74 HSD17B10 (0.48) ALOX15HSD17B10CYP1A2CYP2C9CYP2C19
SCHEMBL15105770 0.72 ACHE (0.47) AKR1C2AKR1C3ALDH1A1GAA
SCHEMBL30343444 0.72 HSD17B10 (0.70) ALOX15HSD17B10CYP1A2CYP2C9CYP2C19
SCHEMBL1597487 0.72 HSD17B10 (0.70) ALOX15HSD17B10CYP1A2CYP2C9CYP2C19
SCHEMBL11440380 0.71 HSD17B10 (0.42) ALOX15HSD17B10CYP1A2CYP2C9CYP2C19
SCHEMBL15105328 0.70 ACHE (0.55) AKR1C2AKR1C3SMN1; SMN2ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7528129-B2 CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-05 US disclosed
US-20060252931-A1 New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-11-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252931-A1 New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions CALCRL, CALCR, CALCA AKR1C2 1483/4885AKR1C3 884/4885ALOX15 3029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.